Neo‑Adjuvant Chemotherapy Followed by Interval Debulking Surgery in Advanced Ovarian Cancer Treatment – a Retrospective Study

Česká verze

Authors: M. Tkáčová ^1,2; B. Vertaková‑ krakovská ^1,2; B. Belohorská ^1,2; V. Miškovská ^1,2; L. Heľpianska ^1,2; D. Ondruš ¹; M. Ondrušová ^3,4; S. Špánik ^1,2; J. Švec ¹
Authors place of work: I. onkologická klinika LF UK, Bratislava, Slovenská republika ¹; Interná‑ onkologická klinika OÚSA, Bratislava, Slovenská republika ²; Ústav experimentálnej onkológie SAV, Bratislava, Slovenská republika ³; Institut biostatistiky a analýz, Masarykova univerzita, Brno ⁴
Published in the journal: Klin Onkol 2009; 22(6): 273-277
Category: Původní práce

Summary

Backgrounds:
Primary debulking surgery and chemotherapy (paclitaxel and carboplatin) remain the standard treatment for advanced ovarian cancer. The size of the residual tumour after primary debulking surgery has proved to be an important prognostic determinant. Complete tumour debulking without any macroscopic residual disease is considered the optimal primary debulking surgery. It is not possible to perform such an aggressive operation in patients with advanced ovarian cancer due to the bad performance status and extensive disease. Neo‑ adjuvant chemotherapy and interval debulking surgery seem to be an effective treatment strategy in this group of patients.

Material and Methods:
The retrospective analysis evaluated the efficiency of interval debulking surgery in correlation with progression‑free and overall survival in patients with advanced ovarian cancer. 38 patients were treated with standard chemotherapy: paclitaxel 175 mg/ m2 and carboplatin 5– 6 AUC every three weeks. According to the clinical response, surgical debulking was considered, after which postoperative chemotherapy was given. Ineligible patients for interval debulking were treated with 2nd line chemotherapy.

Results:
After neo‑ adjuvant chemotherapy, 24 patients of the group of 38 achieved partial remission and interval debulking surgery was indicated. Optimal interval debulking surgery was performed in 12 patients, suboptimal debulking surgery in 12 patients. Of the entire group, 14 patients did not show any adequate response to the primary treatment, they did not have interval debulking surgery indicated and they were treated with 2nd line chemotherapy. Progression‑free survival in patients after optimal debulking was 11 months, median overall survival was not achieved (OS > 42.5 months). Progression‑free survival in patients after suboptimal debulking was 6 months and median overall survival was 33 months. Median overall survival in patients without surgical treatment was 21.5 months.

Conclusion:
The results of the study confirm that neo‑ adjuvant chemotherapy with subsequent interval debulking surgery is a suitable therapeutic approach in primary inoperable patients with advanced ovarian cancer.

Key words:
ovarian cancer – surgery – neo adjuvant therapy – chemotherapy

Zdroje

1. Safaei Diba Ch, Pleško I, Obšitniková A et al. Incidencia zhubných nádorov v Slovenskej republike 2005. Národný onkologický register SR, NCZI 2009.

2. Deo SVS, Hemant G, Shukla NK et al. Neoadjuvant chemotherapy followed by surgical cytoreduction in advanced epithelial ovarian cancer. Indian J Cancer 2006; 43(3): 117– 121.

3. Vergote IB. Neoadjuvant chemotherapy in advanced ovarian cancer. American Society of Clinical Oncology. Educational Book 2004; 285– 291.

4. Rose PG. Neoadjuvant chemotherapy for ovarian cancer. American Society of Clinical Oncology. Educational Book 2004; 276– 284.

5. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a metaanalysis. J Clin Oncol 2002; 20(5): 1248– 1259.

6. Fader AN, Rose PG. Role of Surgery in Ovarian Cancer. J Clin Oncol 2007; 25(20): 2873– 2880.

7. Le T, Shahriari L, Hopkins W et al. Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking. Int J Gynecol Cancer 2006; 16 (3): 986– 990.

8. Vergote I, De Wever I, Tjalma W et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998; 71 (3): 431– 436.

9. Ansquer Y, Leblanc E, Clough K et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma‑ a French multicenter study. Cancer 2001; 91 (12): 2329– 2334.

10. Kuhn W, Rutke S, Späthe K et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 2001; 92 (10): 2585– 2591.

11. Kayikcioglu F, Kose MF, Boran N et al. Neadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001; 11 (6): 466– 470.

12. Mazzeo F, Berliere M, Kerger J et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapyin patients with primarily unresectable, advanced‑stage ovarian cancer. Gynecol Oncol 2003; 90(1):163– 169.

13. Krasner C, Duska L. Management of Women With Newly Diagnosed Ovarian cancer. Seminars in Oncology: Gynecol Cancer Update 2009; 36(2): 91– 101.

14. Vergote I, van Gorp T, Amant F et al. Timing of debulking surgery in advanced ovarian cancer. Int J Gynecol Cancer 2008, 18 (Suppl 1): 11– 19.

15. Thigpen T. The If and when of surgical debulking for ovarian carcinoma. N Engl J Med 2004; 351(24): 2544– 2546.

16. Tesařik Z. Kontroverze v moderní léčbě pokročilého ovariálního karcinomu. Klin Onkol 2002; 15(4): 136– 141.

17. Vergote I, van Gorp T, Amant F et al. Neoadjuvant chemotherapy for ovarian cancer. Oncology (Williston Park) 2005; 19(12): 1615– 1622.